
Anumana
Developing and delivering ECG algorithms enabling early diagnosis and intervention.
USD | 2022 | 2023 |
---|---|---|
Revenues | 0000 | 0000 |
% growth | - | 60 % |
EBITDA | 0000 | 0000 |
Profit | 0000 | 0000 |
EV | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x |
R&D budget | 0000 | 0000 |
Source: Dealroom estimates
Related Content
Anumana is a startup that is revolutionizing cardiac care with cutting-edge AI, industry-leading translational science, and deep electrophysiological data. Anumana's AI solutions enable earlier diagnosis of otherwise hidden diseases, empowering clinicians to intervene with treatments earlier and improve outcomes. Anumana's algorithms and software have the potential to improve procedure accuracy, reduce procedure times, improve medication management, and improve patient safety and outcomes. Anumana has one of the world’s largest electrophysiological data and longitudinal patient history and outcomes in the world. This harmonized, cleaned, and validated dataset was developed from multi-year data partnerships with several health systems from Anumana’s parent company, nference. Anumana's research is conducted on this extensive data platform, and their ECG-AI and EGM-AI algorithms have been validated by over 75 peer-reviewed publications. Anumana is making a profit by providing their AI solutions to healthcare providers and hospitals, and they are different from other businesses in the same industry because they are leveraging cutting-edge AI, industry-leading translational science, and deep electrophysiological data to provide more accurate and timely diagnosis and interventions.
Tech stack
Investments by Anumana
Edit